{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:10:28Z","timestamp":1756858228453,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.leukres.2025.107911","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:20:52Z","timestamp":1752578452000},"page":"107911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinicopathologic, genetic, and prognostic characteristics of single-hit versus multi-hit TP53-mutated chronic lymphocytic leukemia in the era of novel therapies"],"prefix":"10.1016","volume":"156","author":[{"given":"Hamza","family":"Tariq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Vadasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juehua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7574","key":"10.1016\/j.leukres.2025.107911_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.leukres.2025.107911_bib2","article-title":"The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment","volume":"11","author":"Perez-Carretero","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"26","key":"10.1016\/j.leukres.2025.107911_bib3","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"7574","key":"10.1016\/j.leukres.2025.107911_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"issue":"7354","key":"10.1016\/j.leukres.2025.107911_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.leukres.2025.107911_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203483","article-title":"Recent advances in the molecular biology of chronic lymphocytic leukemia: how to define prognosis and guide treatment","volume":"16","author":"Arcari","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.leukres.2025.107911_bib7","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107911_bib8","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","author":"Davids","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107911_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70017","article-title":"Outcomes and prognostic factors in 3306 patients with relapsed\/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: a nationwide study","volume":"8","author":"Rigolin","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.leukres.2025.107911_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/hematology.2024000656","article-title":"Risk-stratification in frontline CLL therapy: standard of care","volume":"2024","author":"Tausch","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.leukres.2025.107911_bib11","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2010.208","article-title":"TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations","volume":"24","author":"Zenz","year":"2010","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2025.107911_bib12","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107911_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2025.107911_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2025.107911_bib15","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2025.107911_bib16","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2025.107911_bib17","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","article-title":"Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL","volume":"7","author":"Griffin","year":"2023","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.leukres.2025.107911_bib18","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-4890","article-title":"Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib","volume":"27","author":"Brieghel","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2025.107911_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.107911_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best. Pract. Res. Clin. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107911_bib21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2025.107911_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.leukres.2016.01.009","article-title":"Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes","volume":"42","author":"Svobodova","year":"2016","journal-title":"Leuk. Res."},{"issue":"18","key":"10.1016\/j.leukres.2025.107911_bib23","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.leukres.2025.107911_bib24","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.leukres.2025.107911_bib25","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.107911_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.107911_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/hematology.2024000556","article-title":"Are TP53 mutations all alike?","volume":"2024","author":"Wong","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.leukres.2025.107911_bib28","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1007\/s00277-024-06054-7","article-title":"Overall survival in TP53-mutated AML and MDS","volume":"103","author":"Puzo","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107911_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-022-03417-1","article-title":"The International Consensus Classification of myelodysplastic syndromes and related entities","volume":"482","author":"Hasserjian","year":"2023","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.leukres.2025.107911_bib30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41375-023-01845-9","article-title":"Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study","volume":"37","author":"Bomben","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2025.107911_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2011.01639.x","article-title":"Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice","volume":"87","author":"Doubek","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107911_bib32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.leu.2402537","article-title":"Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course","volume":"16","author":"Stilgenbauer","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2025.107911_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2025.107911_bib34","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ajh.26595","article-title":"TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: a retrospective analysis","volume":"97","author":"Cherng","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2025.107911_bib35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2025.107911_bib36","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107911_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107911_bib38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:56:08Z","timestamp":1756821368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S0145212625002711"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107911","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic, genetic, and prognostic characteristics of single-hit versus multi-hit TP53-mutated chronic lymphocytic leukemia in the era of novel therapies","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107911"}}